Interferon Treatment for Hepatitis B
Interferon Treatment for Hepatitis B
复制标题
DOI：
10.1016/j.cld.2016.06.002
复制
发表时间：
2016-11-01
影响因子：
5.1
通讯作者：
Lok, Anna S.
中科院分区：
文献类型：
--
作者：
Konerman, Monica A.;Lok, Anna S.
慢性B型肝炎病毒（HBV）感染对公共卫生有重大影响。目前有7种获批的慢性HBV治疗方法，包括标准和聚乙二醇化干扰素（IFN）-α和5种核苷（酸）类似物（NUC）。IFN提供优于NUC的益处，包括有限的治疗持续时间和更高的B e抗原和表面抗原清除率。这些益处需要与IFN治疗的潜在副作用进行权衡。有些患者不应该接受干扰素，因为先进的肝脏疾病或合并症。本文综述了干扰素治疗HBV感染的作用机制、疗效和临床应用。
Chronic hepatitis B virus (HBV) infection has a significant public health impact. There are currently 7 approved therapies for chronic HBV, including standard and pegylated interferon (IFN)-alpha, and 5 nucleos(t)ide analogs (NUCs). IFN offers benefits over NUCs, including a finite duration of therapy and a higher rate of clearance of hepatitis B e antigen and surface antigen. These benefits need to be weighed against the potential adverse effects of IFN therapy. Some patients should not receive IFN because of advanced liver disease or comorbidities. This article reviews the mechanisms of action, efficacy, and clinical use of IFN therapy for HBV infection.